依帕司他治疗糖尿病周围神经病变的疗效及对患者血清IL-6、IL-8、IL-17和IL-23水平的影响

Efficacy of epalrestat in the treatment of diabetic peripheral neuropathy and its effect on serum levels of IL-6,IL-8,IL-17 and IL-23

目的观察依帕司他治疗糖尿病周围神经病变(DPN)的疗效及对患者血清白细胞介素(IL)-6、IL-8、IL-17和IL-23水平的影响。方法选取该院2018年2月至2019年2月确诊的DPN患者98例为研究对象,按随机数字表法分为对照组48例,观察组50例。两组均进行控制血糖治疗,对照组给予硫辛酸口服,观察组在对照组基础上给予依帕司他口服,两组疗程均为4周。比较两组治疗前后正中神经的运动神经传导速度(MNCV)、感觉神经传导速度(SNCV);比较两组治疗前后血清IL-6、IL-8、IL-17和IL-23水平;比较两组临床疗效;观察并记录治疗期间两组的不良反应发生情况。结果治疗后,观察组MNCV、SNCV均高于对照组(P<0.05)。治疗后,观察组IL-6、IL-8、IL-17及IL-23水平均低于对照组(P<0.05)。观察组总有效率为94.00%,高于对照组的83.33%(χ^2=2.597,P<0.05)。治疗期间,观察组出现1例腹胀,1例头晕;对照组出现1例皮疹,1例头晕。结论采用依帕司他对DPN患者进行治疗,可明显改善患者临床症状,降低血清IL-6、IL-8、IL-17及IL-23水平,治疗效果佳,安全性高,值得在临床推广应用。

Objective To observe the efficacy of epalrestat in the treatment of diabetic peripheral neuropathy(DPN)and its effect on serum levels of interleukin(IL)-6,IL-8,IL-17 and IL-23.Methods A total of 98 DPN patients diagnosed in the hospital from February 2018 to February 2019 were selected as the research objects.According to the random number table,they were divided into 48 cases in the control group and 50 cases in the observation group.Two groups were treated with blood glucose control,the control group was given lipoic acid orally,and the observation group was given epalrestat orally on the basis of the control group.The course of treatment for the two groups was 4 weeks.Motor nerve conduction velocity(MNCV)and sensory nerve conduction velocity(SNCV)of median nerve were compared between the two groups before and after treatment.The serum levels of IL-6,IL-8,IL-17 and IL-23 were compared between the two groups before and after treatment.The clinical effects of the two groups were compared,and the incidence of adverse reactions during the treatment was observed and recorded.Results After treatment,the MNCV and SNCV in the observation group were higher than those in the control group(P<0.05).After treatment,the levels of IL-6,IL-8,IL-17 and IL-23 in the observation group were lower than those in the control group(P<0.05).The total effective rate of the observation group was 94.00%,which was higher than 83.33%of the control group(χ^2=2.597,P<0.05).During the treatment,the observation group had 1 case of abdominal distension and 1 case of dizziness;the control group had 1 case of rash and 1 case of dizziness.Conclusion Using epalrestat in the treatment of DPN patients can significantly improve the clinical symptoms of patients,reduce the serum levels of IL-6,IL-8,IL-17 and IL-23,with good therapeutic effect and high safety,which is worthy of clinical application.